Royalty Rights To AMD Drug Spur $175 Million Capital Raise For Ophthotech
This article was originally published in The Pink Sheet Daily
Executive Summary
Money will finance 1,900-patient, 200-site Phase III trial for wet AMD drug Fovista, expected to work in concert with anti-VEGF therapies such as Lucentis to restore eye function. The transaction is just the latest ophthalmology financing involving Novo AS, SV Life Sciences and executives once with Eyetech.